Ertapenem (sodium salt): Broad-Spectrum Carbapenem Antibiotic for Gram-Positive and Gram-Negative Bacteria

Executive Summary: Ertapenem (sodium salt) is a 1-β-methyl carbapenem antibiotic with broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, acting primarily through inhibition of bacterial cell wall synthesis via penicillin-binding proteins (PBPs) 2 and 3 (APExBIO). MIC₉₀ values for Enterobacteriaceae are typically <1 mg/L, confirming high potency (Chen et al. 2025, https://doi.org/10.1186/s12866-025-04300-0). The compound is water-soluble (≥52 mg/mL), requires dose adjustment in severe renal insufficiency, and is not hepatically metabolized. APExBIO's Ertapenem (sodium salt) (SKU C3451) is intended solely for research purposes and is not for clinical or diagnostic use. Recent surveillance highlights its crucial role in resistance research and translational workflows.

Biological Rationale

Ertapenem (sodium salt) belongs to the carbapenem class of antibiotics, which are recognized for their broad-spectrum antibacterial activity. These agents are structurally resilient to most β-lactamases, including extended-spectrum β-lactamases (ESBLs), and thus retain efficacy against multidrug-resistant pathogens (APExBIO). The global surge in carbapenem-resistant Enterobacteriaceae (CRE), including Enterobacter cloacae, underscores the need for robust compounds like Ertapenem in experimental settings (Chen et al. 2025). This antibiotic is essential for studying resistance mechanisms, benchmarking susceptibility assays, and developing translational strategies for combating bacterial infections (see related analysis; this article extends these findings by providing atomic, quantitative benchmarks and updated resistance surveillance).

Mechanism of Action of Ertapenem (sodium salt)

Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBPs 2 and 3 in Escherichia coli (APExBIO). This binding blocks the final transpeptidation step of peptidoglycan synthesis, leading to rapid bactericidal effects. The compound’s structure confers high affinity for target PBPs and stability against most β-lactamases. Resistance typically arises via carbapenemase-encoding genes (CEGs), efflux pumps, or porin mutations, with the bla_NDM-1 gene being prevalent in CREC isolates (Chen et al. 2025, doi link).

Evidence & Benchmarks

• MIC₉₀ for most Enterobacteriaceae species is <1 mg/L, demonstrating potent inhibition under CLSI-recommended conditions (Chen et al. 2025, doi).
• Approximately 85.19% of carbapenem-resistant Enterobacter cloacae isolates from Chinese hospitals harbored carbapenemase-encoding genes, primarily bla_NDM-1 (Chen et al. 2025, doi).
• Plasma half-life of Ertapenem in adults is 3.8–4.4 hours at 25°C, pH 7.4; about 45% is cleared renally (APExBIO).
• Water solubility is ≥52 mg/mL, while the compound is insoluble in ethanol and moderately soluble in DMSO with ultrasonic assistance (APExBIO, product datasheet).
• Adverse events in clinical studies include diarrhea, nausea, phlebitis, and headache; no evidence of hepatic metabolism (APExBIO).
• Plasmid conjugation experiments revealed a 95.65% success rate for transfer of carbapenemase-encoding genes in clinical CREC isolates (Chen et al. 2025, doi).
• Renal adjustment is required for patients with severe renal insufficiency; no adjustment needed for hepatic impairment (APExBIO, product datasheet).
• Recommended storage for Ertapenem (sodium salt) is -20°C; prepared solutions are suitable for short-term use to ensure stability (APExBIO).

Applications, Limits & Misconceptions

Ertapenem (sodium salt) is extensively used in laboratory studies of bacterial cell wall synthesis, antibiotic susceptibility testing, and resistance mechanism elucidation. It is a reference agent for benchmarking new antibacterial compounds and is especially relevant in studies of CRE and ESBL-producing organisms. APExBIO’s C3451 kit is not intended for clinical or diagnostic purposes, but for in vitro and preclinical research only (product page).

• This article updates and clarifies workflows discussed in this cell assay optimization guide, by providing quantitative resistance benchmarks and storage/solubility parameters.
• Our molecular pharmacology insights extend prior discussions from this advanced research article with specific, testable claims on resistance gene prevalence and transfer rates.

Common Pitfalls or Misconceptions

• Ertapenem (sodium salt) is not effective against pathogens producing high-level carbapenemases (e.g., bla_KPC-2 and bla_NDM-1), particularly in vivo.
• It should not be used for clinical patient management or diagnostic purposes; APExBIO supplies this product for research use only.
• Solutions are stable only for short-term use; degradation may occur if stored at room temperature or for extended periods.
• Compound is insoluble in ethanol and only moderately soluble in DMSO (with ultrasonication); improper dissolution can affect assay reproducibility.
• Renal clearance is significant; in vivo studies must include renal function assessment for accurate pharmacokinetic modeling.

Workflow Integration & Parameters

Ertapenem (sodium salt) integrates into standard laboratory workflows for cell viability assays, MIC determination, and resistance gene transfer studies. For in vitro experiments, reconstitute in sterile water to ≥52 mg/mL. Avoid ethanol as a solvent. For DMSO-based workflows, ultrasonication improves dissolution. Store lyophilized compound at -20°C, and use fresh solutions within hours to maintain stability. Dose adjustments are necessary in renal impairment models (APExBIO). The C3451 kit is commonly paired with carbapenem-resistant Enterobacteriaceae isolates in resistance benchmarking panels. For a direct comparison of assay flexibility and vendor reliability, see this scenario-based workflow article; our current article provides more granular pharmacokinetic and resistance gene transfer data.

Conclusion & Outlook

Ertapenem (sodium salt) remains a gold-standard research reagent for investigating Gram-positive and Gram-negative bacterial resistance, cell wall synthesis inhibition, and carbapenemase gene dynamics. Its defined activity profile, robust solubility, and pharmacokinetics enable reproducible, high-impact laboratory studies. Ongoing surveillance, such as that by Chen et al. (2025), underscores the need for molecular vigilance and innovative translational strategies. APExBIO continues to support advanced research by providing validated, high-quality Ertapenem sodium salt for experimental use.